Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.41 |
| ▸ | MANBA | O00462 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16282667 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL21924362 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL18463823 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL24558370 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL21924361 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL24849486 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL21103713 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL22748686 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL20855308 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB | |
| SCHEMBL29398809 | 1.00 | L3MBTL1 (0.56) | L3MBTL1NANPMANBALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220168410-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | PFIZER INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220152181-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | PFIZER INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20200061177-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | PFIZER INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061177-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | WIZ, GNE, ENGASE | L3MBTL1 713/4885NANP 155/4885MANBA 172/4885 |
| US-20220168410-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | WIZ, GNE, ENGASE | L3MBTL1 713/4885NANP 155/4885MANBA 172/4885 |
| US-20220152181-A1 | ESCHERICHIA COLI COMPOSITIONS AND METHODS THEREOF | MRPL21, DDOST, STT3A | L3MBTL1 1794/4885NANP 240/4885MANBA 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.